Demographics of patients who completed at least 1 randomized study transfusion
| Characteristic . | Overall . | ≤10-day arm . | ≥30-day arm . |
|---|---|---|---|
| Age, median (IQR) | 28.5 (23-34) | 29 (24-34) | 27 (23-33) |
| Sex, female, n (%) | 16 (61.5) | 6 (46.2) | 10 (77.0) |
| Race, Black, n (%) | 32 (100) | 13 (100) | 13 (100) |
| Ethnicity, not Hispanic, n (%) | 32 (100) | 13 (100) | 13 (100) |
| Sickle cell genotype, HbSS, n (%) | 32 (100) | 13 (100) | 13 (100) |
| Height, median (IQR), cm | 168.9 (160.3-174.4) | 170.2 (161.3-175.3) | 165.4 (157.5-173.9) |
| Weight, median (IQR), kg | 60.3 (55.1-68.1) | 64.4 (59.0-71.4) | 58.9 (48.1-63.7) |
| Blood type, ABO, n (%) | |||
| A | 7 (27) | 3 (23.1) | 4 (30.8) |
| B | 4 (15.4) | 2 (15.4) | 2 (15.4) |
| AB | 0 | 0 | 0 |
| O | 15 (57.7) | 8 (61.5) | 7 (53.8) |
| Rh(D), positive, n (%) | 25 (96.2) | 13 (100) | 12 (92.3) |
| Comorbidities, n (%) | |||
| Iron overload | 20 (76.9) | 9 (69,2) | 11 (84.6) |
| Chronic pain | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Asthma/COPD | 9 (34.6) | 5 (38.5) | 4 (30.8) |
| Pulmonary hypertension | 6 (23.1) | 4 (30.8) | 2 (15.4) |
| G6PD deficiency | 1 (3.8) | 1 (7.7) | 0 |
| Avascular necrosis | 3 (11.5) | 2 (15.4) | 1 (7.7) |
| Retinopathy | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Pulmonary embolus | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Diabetes | 1 (3.8) | 0 | 1 (7.7) |
| Chronic kidney disease | 6 (23.1) | 3 (23.1) | 3 (23.1) |
| Priapism | 3 (11.5) | 2 (15.4) | 1 (7.7) |
| Hypertension | 6 (23.1) | 4 (30.8) | 2 (15.4) |
| Stroke | 15 (57.7) | 7 (53.8) | 8 (61.5) |
| Moyamoya | 7 (26.9) | 3 (23.1) | 4 (30.8) |
| Seizure disorder | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Acute chest syndrome | 6 (23.1) | 4 (30.8) | 2 (15.4) |
| Chronic therapies (in addition to transfusion) | |||
| Hydroxyurea | 4 (15.4) | 3 (23.1) | 1 (7.7) |
| Iron chelation | 22 (84.6) | 11 (84.6) | 11 (84.6) |
| Hospitalizations in the year before consent, median (IQR) | |||
| ED admissions | 2.5 (1.0-7.5) | 4.0 (0.5-8.0) | 2.0 (1.0-8.0) |
| Hospital admissions | 2.0 (1.0-3.0) | 2.0 (0-2.5) | 2.0 (1.0-3.5) |
| Characteristic . | Overall . | ≤10-day arm . | ≥30-day arm . |
|---|---|---|---|
| Age, median (IQR) | 28.5 (23-34) | 29 (24-34) | 27 (23-33) |
| Sex, female, n (%) | 16 (61.5) | 6 (46.2) | 10 (77.0) |
| Race, Black, n (%) | 32 (100) | 13 (100) | 13 (100) |
| Ethnicity, not Hispanic, n (%) | 32 (100) | 13 (100) | 13 (100) |
| Sickle cell genotype, HbSS, n (%) | 32 (100) | 13 (100) | 13 (100) |
| Height, median (IQR), cm | 168.9 (160.3-174.4) | 170.2 (161.3-175.3) | 165.4 (157.5-173.9) |
| Weight, median (IQR), kg | 60.3 (55.1-68.1) | 64.4 (59.0-71.4) | 58.9 (48.1-63.7) |
| Blood type, ABO, n (%) | |||
| A | 7 (27) | 3 (23.1) | 4 (30.8) |
| B | 4 (15.4) | 2 (15.4) | 2 (15.4) |
| AB | 0 | 0 | 0 |
| O | 15 (57.7) | 8 (61.5) | 7 (53.8) |
| Rh(D), positive, n (%) | 25 (96.2) | 13 (100) | 12 (92.3) |
| Comorbidities, n (%) | |||
| Iron overload | 20 (76.9) | 9 (69,2) | 11 (84.6) |
| Chronic pain | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Asthma/COPD | 9 (34.6) | 5 (38.5) | 4 (30.8) |
| Pulmonary hypertension | 6 (23.1) | 4 (30.8) | 2 (15.4) |
| G6PD deficiency | 1 (3.8) | 1 (7.7) | 0 |
| Avascular necrosis | 3 (11.5) | 2 (15.4) | 1 (7.7) |
| Retinopathy | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Pulmonary embolus | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Diabetes | 1 (3.8) | 0 | 1 (7.7) |
| Chronic kidney disease | 6 (23.1) | 3 (23.1) | 3 (23.1) |
| Priapism | 3 (11.5) | 2 (15.4) | 1 (7.7) |
| Hypertension | 6 (23.1) | 4 (30.8) | 2 (15.4) |
| Stroke | 15 (57.7) | 7 (53.8) | 8 (61.5) |
| Moyamoya | 7 (26.9) | 3 (23.1) | 4 (30.8) |
| Seizure disorder | 2 (7.7) | 1 (7.7) | 1 (7.7) |
| Acute chest syndrome | 6 (23.1) | 4 (30.8) | 2 (15.4) |
| Chronic therapies (in addition to transfusion) | |||
| Hydroxyurea | 4 (15.4) | 3 (23.1) | 1 (7.7) |
| Iron chelation | 22 (84.6) | 11 (84.6) | 11 (84.6) |
| Hospitalizations in the year before consent, median (IQR) | |||
| ED admissions | 2.5 (1.0-7.5) | 4.0 (0.5-8.0) | 2.0 (1.0-8.0) |
| Hospital admissions | 2.0 (1.0-3.0) | 2.0 (0-2.5) | 2.0 (1.0-3.5) |
Differences not statistically significant, P > .1.
COPD, chronic obstructive pulmonary disease; ED, emergency department; HbSS, hemoglobin SS; IQR, interquartile range.